503 research outputs found
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet
none2openBronte G.; Rolfo C.Bronte, G.; Rolfo, C
Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
In the past decade, the advent of targeted therapy led to a silent revolution
in the war against lung cancer and a significant evolution on the concept
of Phase I clinical trials design. Thanks to the specificity of their target,
the new drugs have radically changed NSCLC treatment, leading to the development
of personalized strategies. The accelerated approval of the first
ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III
randomized, clinical trial, has been an amazing success story in lung cancer
research, marking the beginning of a new decade of targeted drugs development,
characterized by modern, biomarker-driven, early clinical trial design
and shorter times for clinical approval. Is Ceritinib a new panacea for the
treatment of ALK-rearranged NSCLC? We aimed to discuss the reasons of
such success, including the new emerging questions, regarding mechanisms
of acquired resistance, and the best treatment algorithm for ALK-rearranged
NSCLC patients
- …